Replies to post #18743 on Ayala Pharmaceuticals Inc (ADXS)

[investorluck]

Case in point, ADXS presented the final phase II data, in oral late-breaking format, at SGO and phase I high dose data at NCRI last month. They could have waited for asco, but presented when data was available.